Follow us
Search
For health professionalsContact usPress Enter to search. For products, try the shop filter.
(08) 6110 0570
admin@pdchealthhub.com.auPress Enter to search. For products, try the shop filter.
(08) 6110 0570admin@pdchealthhub.com.auThe only full smart pen on the Australian market. A reusable Bluetooth pen whose app holds a dose calculator, tracks active insulin and shows Guardian 4 glucose on the same screen.
What it is, how it works and who it tends to suit.
A reusable Bluetooth insulin pen, sold in Australia as part of the Smart MDI system. Every dose is logged to the InPen app, which calculates doses, tracks the insulin still working and shows Guardian 4 sensor glucose on the same screen.
The InPen is a reusable insulin pen with a small amount of electronics inside. You load a 3 mL cartridge, dial the dose and inject exactly as you would with any pen. The difference is that the pen records the units and the time and sends them to the InPen app over Bluetooth, so the log builds itself.
The app is where the value sits. It holds a dose calculator that works from your insulin to carbohydrate ratio, your insulin sensitivity factor, your target glucose and your duration of insulin action, with up to four time periods across the day. It tracks active insulin, so a correction dose is not stacked on top of one you had forgotten. It sends dose reminders, logs every dose automatically and produces reports you can share.
The calculator accepts a glucose reading between 1.1 and 33.3 mmol/L and a carbohydrate entry between 0 and 300 grams, and it rounds its recommendation down to the nearest half unit. At a glucose of 3.1 mmol/L or below it recommends fast acting carbohydrate rather than insulin.
In Australia the InPen app shows Guardian 4 sensor glucose alongside your doses. It does not read a Dexcom or a FreeStyle Libre sensor here, which is the single most important thing to settle before you buy. Finger prick readings can pre-populate through Apple Health if they are less than ten minutes old.
The InPen does not adjust your insulin and it does not deliver anything on its own. It is a pen that reports and a calculator that advises, using settings a clinician sets up with you. Your long acting insulin stays in its own pen, and those doses are not logged automatically.
A single dose is capped at 30 units, so a larger dose is split, with the larger part given first. The pen works between 5 and 37 degrees with insulin loaded and should not be kept in the fridge. In Australia it is sold in blue only.
Checked 13 November 2026
Book with a credentialled diabetes educator. We look at your current doses, your ratios and your sensor, and tell you whether this pen would change anything.
Book a CDE consultSmart pens are bought privately here, so this is where the practical detail sits.
Written neutrally. We are not paid by the manufacturer to say any of this.
Select a photo to open it larger.
Checked against the Australian MiniMed product pages, the Australian InPen instructions for use and the Therapeutic Goods Administration register on 13 November 2026.
The Australian product pages list the pen with NovoRapid, Fiasp and Insulin Aspart. The instructions for use also describe a separate model for Humalog and Lyumjev, which we could not find offered in Australia, so confirm the model with MiniMed before you order.
We do not publish a price for this pen. We do not sell it and the manufacturer sets it.
Book with one of our credentialled diabetes educators. We go through your current doses, your ratios and your glucose data, and tell you plainly whether a smart pen would change anything for you or whether something else would do more.
Or go straight to a service
Phone (08) 6110 0570 · Smart pens are not NDSS or PBS subsidised · Medicare, NDIS, DVA and private options across our services
For GPs, endocrinologists and nurse practitioners
Use our online referral form and tick Diabetes Education. Our credentialled diabetes educators review doses, ratios and sensor data, set a smart pen up where it suits, and send a summary back to you.
